These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 37340243)

  • 1. Intraperitoneal paclitaxel combined with FOLFOX/CAPOX plus bevacizumab for colorectal cancer with peritoneal carcinomatosis (the iPac-02 trial): study protocol of a single arm, multicenter, phase 2 study.
    Murono K; Yokoyama Y; Nozawa H; Sasaki K; Emoto S; Matsuzaki H; Kashiwabara K; Ishigami H; Gohda Y; Yamaguchi H; Kitayama J; Ishihara S
    Int J Colorectal Dis; 2023 Jun; 38(1):173. PubMed ID: 37340243
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety of intraperitoneal paclitaxel combined with conventional chemotherapy for colorectal cancer with peritoneal carcinomatosis: a phase I trial.
    Murono K; Nagata H; Ishimaru K; Emoto S; Kaneko M; Hiyoshi M; Sasaki K; Otani K; Shuno Y; Nishikawa T; Tanaka T; Hata K; Kawai K; Nozawa H; Muro K; Ishihara S
    Cancer Chemother Pharmacol; 2019 Jan; 83(1):145-150. PubMed ID: 30386886
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of intraperitoneally administered paclitaxel for colorectal cancer with peritoneal metastases.
    Murono K; Nozawa H; Nagata H; Ishimaru K; Sonoda H; Emoto S; Kaneko M; Sasaki K; Otani K; Kawai K; Muro K; Ishihara S
    Int J Colorectal Dis; 2020 Oct; 35(10):1945-1949. PubMed ID: 32495229
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Weekly paclitaxel plus ramucirumab versus weekly nab-paclitaxel plus ramucirumab for unresectable advanced or recurrent gastric cancer with peritoneal dissemination refractory to first-line therapy-the P-SELECT trial (WJOG10617G)-a randomised phase II trial by the West Japan Oncology Group.
    Hirata K; Hamamoto Y; Ando M; Imamura CK; Yoshimura K; Yamazaki K; Hironaka S; Muro K
    BMC Cancer; 2020 Jun; 20(1):548. PubMed ID: 32532230
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intraperitoneal irinotecan with concomitant FOLFOX and bevacizumab for patients with unresectable colorectal peritoneal metastases: protocol of the multicentre, open-label, phase II, INTERACT-II trial.
    van de Vlasakker VCJ; Guchelaar NAD; van den Heuvel TBM; Lurvink RJ; van Meerten E; Bax RJF; Creemers GM; van Hellemond IEG; Brandt-Kerkhof ARM; Madsen EVE; Nederend J; Koolen SLW; Nienhuijs SW; Kranenburg O; de Hingh IHJT; Verhoef C; Mathijssen RHJ; Burger JWA; ;
    BMJ Open; 2024 Jan; 14(1):e077667. PubMed ID: 38238055
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Perioperative systemic therapy and cytoreductive surgery with HIPEC versus upfront cytoreductive surgery with HIPEC alone for isolated resectable colorectal peritoneal metastases: protocol of a multicentre, open-label, parallel-group, phase II-III, randomised, superiority study (CAIRO6).
    Rovers KP; Bakkers C; Simkens GAAM; Burger JWA; Nienhuijs SW; Creemers GM; Thijs AMJ; Brandt-Kerkhof ARM; Madsen EVE; Ayez N; de Boer NL; van Meerten E; Tuynman JB; Kusters M; Sluiter NR; Verheul HMW; van der Vliet HJ; Wiezer MJ; Boerma D; Wassenaar ECE; Los M; Hunting CB; Aalbers AGJ; Kok NFM; Kuhlmann KFD; Boot H; Chalabi M; Kruijff S; Been LB; van Ginkel RJ; de Groot DJA; Fehrmann RSN; de Wilt JHW; Bremers AJA; de Reuver PR; Radema SA; Herbschleb KH; van Grevenstein WMU; Witkamp AJ; Koopman M; Haj Mohammad N; van Duyn EB; Mastboom WJB; Mekenkamp LJM; Nederend J; Lahaye MJ; Snaebjornsson P; Verhoef C; van Laarhoven HWM; Zwinderman AH; Bouma JM; Kranenburg O; van 't Erve I; Fijneman RJA; Dijkgraaf MGW; Hemmer PHJ; Punt CJA; Tanis PJ; de Hingh IHJT; ;
    BMC Cancer; 2019 Apr; 19(1):390. PubMed ID: 31023318
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I Study of Intraperitoneal Administration of Paclitaxel Combined with S-1 Plus Cisplatin for Gastric Cancer with Peritoneal Metastasis.
    Kobayashi D; Ishigami H; Kanda M; Tanaka C; Yamaguchi H; Kitayama J; Kodera Y
    Oncology; 2020; 98(1):48-52. PubMed ID: 31487733
    [TBL] [Abstract][Full Text] [Related]  

  • 8. First-line palliative systemic therapy alternated with electrostatic pressurised intraperitoneal aerosol chemotherapy (oxaliplatin) for isolated unresectable colorectal peritoneal metastases: protocol of a multicentre, single-arm, phase II study (CRC-PIPAC-II).
    Lurvink RJ; Rauwerdink P; Rovers KP; Wassenaar ECE; Deenen MJ; Nederend J; Huysentruyt CJR; van 't Erve I; Fijneman RJA; van der Hoeven EJRJ; Seldenrijk CA; Constantinides A; Kranenburg O; Los M; Herbschleb KH; Thijs AMJ; Creemers GM; Burger JWA; Wiezer MJ; Nienhuijs SW; Boerma D; de Hingh IHJT
    BMJ Open; 2021 Mar; 11(3):e044811. PubMed ID: 33785492
    [TBL] [Abstract][Full Text] [Related]  

  • 9. First-line palliative systemic therapy alternated with oxaliplatin-based pressurized intraperitoneal aerosol chemotherapy for unresectable colorectal peritoneal metastases: A single-arm phase II trial (CRC-PIPAC-II).
    Rauwerdink P; van de Vlasakker VCJ; Wassenaar ECE; Rovers KP; Los M; Herbschleb KH; Creemers GM; Thijs AMJ; Raicu MG; Huysentruyt CJR; van der Hoeven EJRJ; Nederend J; Peeters RYM; Deenen MJ; Elias SG; Fijneman RJA; Constantinides A; Kranenburg O; Burger PWA; Nienhuijs SW; Wiezer RJ; Lurvink RJ; de Hingh IHJT; Boerma D
    Eur J Surg Oncol; 2024 Sep; 50(9):108487. PubMed ID: 38905732
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I study of intraperitoneal irinotecan combined with palliative systemic chemotherapy in patients with colorectal peritoneal metastases.
    van Eerden RAG; de Boer NL; van Kooten JP; Bakkers C; Dietz MV; Creemers GM; Buijs SM; Bax R; de Man FM; Lurvink RJ; Diepeveen M; Brandt-Kerkhof ARM; van Meerten E; Koolen SLW; de Hingh IHJT; Verhoef C; Mathijssen RHJ; Burger JWA
    Br J Surg; 2023 Oct; 110(11):1502-1510. PubMed ID: 37467389
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase I study of intraperitoneal paclitaxel combined with gemcitabine plus nab-paclitaxel for pancreatic cancer with peritoneal metastasis.
    Takahara N; Nakai Y; Ishigami H; Saito K; Sato T; Hakuta R; Ishigaki K; Saito T; Hamada T; Mizuno S; Kogure H; Yamashita H; Isayama H; Seto Y; Koike K
    Invest New Drugs; 2021 Feb; 39(1):175-181. PubMed ID: 32772340
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Concomitant intraperitoneal and systemic chemotherapy for extensive peritoneal metastases of colorectal origin: protocol of the multicentre, open-label, phase I, dose-escalation INTERACT trial.
    de Boer NL; Brandt-Kerkhof ARM; Madsen EVE; Diepeveen M; van Meerten E; van Eerden RAG; de Man FM; Bouamar R; Koolen SLW; de Hingh IHJT; Bakkers C; Rovers KP; Creemers GM; Deenen MJ; Kranenburg OW; Constantinides A; Mathijssen RHJ; Verhoef C; Burger JWA; ;
    BMJ Open; 2019 Dec; 9(12):e034508. PubMed ID: 31818845
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized Phase II Trial of CapOX plus Bevacizumab and CapIRI plus Bevacizumab as First-Line Treatment for Japanese Patients with Metastatic Colorectal Cancer (CCOG-1201 Study).
    Nakayama G; Mitsuma A; Sunagawa Y; Ishigure K; Yokoyama H; Matsui T; Nakayama H; Nakata K; Ishiyama A; Asada T; Umeda S; Ezaka K; Hattori N; Takami H; Kobayashi D; Tanaka C; Kanda M; Yamada S; Koike M; Fujiwara M; Fujii T; Murotani K; Ando Y; Kodera Y
    Oncologist; 2018 Aug; 23(8):919-927. PubMed ID: 30049885
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BEV-IP: Perioperative chemotherapy with bevacizumab in patients undergoing cytoreduction and intraperitoneal chemoperfusion for colorectal carcinomatosis.
    Willaert W; Van Der Speeten K; Liberale G; Ceelen W
    BMC Cancer; 2015 Dec; 15():980. PubMed ID: 26673788
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gastrointestinal perforation in metastatic colorectal cancer patients with peritoneal metastases receiving bevacizumab.
    Roohullah A; Wong HL; Sjoquist KM; Gibbs P; Field K; Tran B; Shapiro J; Mckendrick J; Yip D; Nott L; Gebski V; Ng W; Chua W; Price T; Tebbutt N; Chantrill L
    World J Gastroenterol; 2015 May; 21(17):5352-8. PubMed ID: 25954110
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Conversion Surgery Post-Intraperitoneal Paclitaxel and Systemic Chemotherapy for Gastric Cancer Carcinomatosis Peritonei. Are We Ready?
    Chan DY; Syn NL; Yap R; Phua JN; Soh TI; Chee CE; Nga ME; Shabbir A; So JB; Yong WP
    J Gastrointest Surg; 2017 Mar; 21(3):425-433. PubMed ID: 27981493
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A prospective multicenter phase II study evaluating multimodality treatment of patients with peritoneal carcinomatosis arising from appendiceal and colorectal cancer: the COMBATAC trial.
    Glockzin G; Rochon J; Arnold D; Lang SA; Klebl F; Zeman F; Koller M; Schlitt HJ; Piso P
    BMC Cancer; 2013 Feb; 13():67. PubMed ID: 23391248
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcomes of a Phase II Study of Intraperitoneal Paclitaxel plus Systemic Capecitabine and Oxaliplatin (XELOX) for Gastric Cancer with Peritoneal Metastases.
    Chia DKA; Sundar R; Kim G; Ang JJ; Lum JHY; Nga ME; Goh GH; Seet JE; Chee CE; Tan HL; Ho J; Ngoi NYL; Lee MXW; Muthu V; Chan GHJ; Pang ASL; Ang YLE; Choo JRE; Lim JSJ; Teh JL; Lwin A; Soon Y; Shabbir A; So JBY; Yong WP
    Ann Surg Oncol; 2022 Dec; 29(13):8597-8605. PubMed ID: 36070113
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of Duration and Effects of 3 vs 6 Months of Adjuvant Chemotherapy in High-Risk Stage II Colorectal Cancer: A Subgroup Analysis of the TOSCA Randomized Clinical Trial.
    Petrelli F; Labianca R; Zaniboni A; Lonardi S; Galli F; Rulli E; Rosati G; Corallo S; Ronzoni M; Cardellino GG; Mattioli R; Mambrini A; Ciuffreda L; Banzi M; Pusceddu V; Maiello E; Zampino M; Zagonel V; Marchetti P; Corsi D; Rimassa L; Cinieri S; Sobrero A
    JAMA Oncol; 2020 Apr; 6(4):547-551. PubMed ID: 32053133
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genistein combined with FOLFOX or FOLFOX-Bevacizumab for the treatment of metastatic colorectal cancer: phase I/II pilot study.
    Pintova S; Dharmupari S; Moshier E; Zubizarreta N; Ang C; Holcombe RF
    Cancer Chemother Pharmacol; 2019 Sep; 84(3):591-598. PubMed ID: 31203390
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.